Sitemap - 2024 - Big Pharma Sharma

ASH Part 2: Anito-cel is off to the races, but will it be fast enough to catch-up to Cilta-cel?

ASH 2024 | Part 1: Miltenyi and Galapagos Aim Big in CAR-T, but Gaps Remain

Free Posts Starter Pack

Two things I think coming out of SITC 2024

Flipping the Script on Failed Immuno-Oncology Targets: The Case for “Inverse-I/O” in Autoimmune Diseases

Priority Review Voucher (PRV) Market Update – Big Pharma Unloading its Ammo

TIGIT: Too Legit to Quit? Or Just Can't Hit?

Three Major Implications Coming out of ESMO 2024

What the Ivonescimab Data at WCLC Tells Us About China's Role in Drug Development

Two charts that highlight the future of GLP-1s after Diabetes and Obesity

Rethinking the FDA, Innovation, and the Regulatory State: Parsing Vivek and Balaji’s Vision

Why You Should Be Paying Attention to the Emerging IgAN Market

ESMO 2024: My Most Interesting Abstracts

What the Artiva IPO says about the state of cell therapy for autoimmune disease

Safety signals in Lyell’s ROR-1 CAR-T data put key strategic decisions in focus

Can Roche’s COLUMVI threaten the CAR-T renaissance in DLBCL?

ASCO 2024 Temperature Check - Part 2

ASCO 2024 Temperature Check – Part One

Mini ASCO 2024 Preview: An Emerging Battle in Frontline Melanoma

The Renaissance of Psychedelics: Charting New Paths in Mental Health Treatment

ASCO 2024: Most Interesting Data Upcoming at the Conference

CD19 Bispecifics: The Harbinger of Challenges for Autoimmune CAR-T Therapies

Some signs of life for new IL-2 variants

Deconstructing GRANITE's Downfall: Perils for the Neoantigen Vaccine Field?

Bayer's Renaissance: A Roadmap for Revival

What the BCMA CAR-T Adcom Revealed About the Field's Future

AACR 2024 Most Interesting Abstract Titles

Updated Cell Therapy Autoimmune Landscape

A TIL-ing Odyssey Finally Ends in Approval for Iovance's AMTAGVI

An Interview with AI About Its Role in Drug Development

A Few Charts that Outline the Dearth of Innovation in TCR-T Cell Therapies

Big Pharma Sharma's Bullets: (Over)reacting to Recent Industry News

The Next Phase: How BioNTech and Moderna Are Positioning For Their Post-COVID Eras

Sponsored Posts

On the Ground at JPM: Key Themes that Could Define Big Pharma Companies in 2024

AstraZeneca’s build towards becoming an immune cell therapy leader